OnKure Therapeutics (NASDAQ:OKUR) Announces Quarterly Earnings Results, Misses Expectations By $0.51 EPS

OnKure Therapeutics (NASDAQ:OKUR) released its quarterly earnings results on Monday. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51), Zacks reports.

OnKure Therapeutics Trading Down 1.2 %

Shares of OnKure Therapeutics stock traded down $0.06 on Monday, hitting $4.96. 17,420 shares of the company traded hands, compared to its average volume of 82,185. OnKure Therapeutics has a 12-month low of $4.57 and a 12-month high of $20.00. The company’s 50-day simple moving average is $6.11. The company has a market capitalization of $16.58 million, a P/E ratio of -0.41 and a beta of 0.28.

Analyst Ratings Changes

A number of research analysts have weighed in on OKUR shares. Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Leerink Partners assumed coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 target price for the company. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, OnKure Therapeutics presently has an average rating of “Buy” and an average price target of $36.00.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.